...to rhMBL excluding Nordic countries from NatImmune in 2005. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN), Bridgewater, N.J. NatImmune A/S...

...papillomas. NatImmune’s COU-1, a tumor-specific monoclonal antibody, is in Phase I/II testing for colon cancer. NatImmune A/S...

...rights to the compound excluding Nordic countries from NatImmune. Enzon Pharmaceuticals Inc. (ENZN), Bridgewater, N.J. NatImmune A/S...

...Hospital 2004 Cancer Joint development of new cancer therapeutics, vaccines and diagnostics; expanded in 2005 NatImmune...
...leads for therapy and in vivo diagnostics against a clinically validated colon cancer target from NatImmune...

...to recombinant human mannan-binding lectin (rhMBL) to prevent severe infections in MBL-deficient persons undergoing chemotherapy. NatImmune...
...and marketing. The compound has completed Phase I testing. Enzon Pharmaceuticals Inc. (ENZN), Bridgewater, N.J. NatImmune A/S...

...to recombinant human mannan-binding lectin (rhMBL) to prevent severe infections in MBL-deficient persons undergoing chemotherapy. NatImmune...

...antibody libraries and screening technologies to develop human antibodies against a colon cancer target from Natimmune...
...will jointly develop resulting antibodies and share costs and revenues. Affitech A/S , Oslo, Norway Natimmune A/S...

...will evaluate the production of the therapeutic protein mannan-binding lectin (MBL) on CRXL's PER.C6 cells. NatImmune...
...payment and annual fees, and is eligible for royalties. MBL, a natural human protein, is NatImmune's...
...prevention of infections in cancer patients undergoing chemotherapy. Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands NatImmune A/S...